Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer

Wills, Ken N., Maneval, Daniel C., Menzel, Patricia, Harris, Matthew P., Sutjipto, Suganto, Vaillancourt, Mei-Ting, Huang, Whei-Mei, Johnson, Duane E., Anderson, Scott C., Wen, Shu Fen, Bookstein, Robert, Shepard, H. Michael, Gregory, Richard J.·1994·Human Gene Therapy

Abstract

We have constructed recombinant human adenoviruses that express wild-type human p53 under the control of either the Ad 2 major late promoter (MLP) or the human cytomegalovirus (CMV) immediate early gene promoter. Each construct replaces the Ad 5 E1a and E1b coding sequences necessary for viral replication with the p53 cDNA and MLP or CMV promoter. These p53/Ad recombinants are able to express p53 protein in a dose-dependent manner in infected human cancer cells. Tumor suppressor activity of the expressed p53 protein was assayed by several methods. [3H]Thymidine incorporation assays showed that the recombinant adenoviruses were capable of inhibiting DNA synthesis in a p53-specific, dose-dependent fashion. Ex vivo treatment of Saos-2 tumor cells, followed by injection of the treated cells into nude mice, led to complete tumor suppression using the MLP/p53 recombinant. Following a single injection of CMV/p53 recombinant adenovirus into the peritumoral space surrounding an in vivo established tumor derived from a human small cell lung carcinoma cell line (NIH-H69), we were able to detect p53 mRNA in the tumors at 2 and 7 days post-injection. Continued treatment of established H69 tumors with MLP/p53 recombinant led to reduced tumor growth and increased survival time compared to control treated animals. These results indicate that recombinant adenoviruses expressing wild-type p53 may be useful vectors for gene therapy of human cancer. Introduction of the p53 tumor suppressor gene into tumors bearing p53 mutations can inhibit cellular proliferation and tumorigenicity. Wills et al. describe replication-deficient recombinant adenoviruses directing expression of human p53 both in vitro and in vivo. They show that adenovirus-mediated expression of wild-type p53 in p53 altered tumors can suppress proliferation and inhibit tumorigenicity in ex vivo and in vivo cancer models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.1994.5.9-1079

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 233

Metadata

Authors
Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M.-T., Huang, W.-M., Johnson, D. E., Anderson, S. C., Wen, S. F., Bookstein, R., Shepard, H. M., & Gregory, R. J.
Venue
Human Gene Therapy
Published
1994-09
Volume
5
Issue
9
Pages
1079-1088
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W1989834582
Cited by
233
References
4
FWCI
10.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer. https://app.cochat.ai/papers/10.1089/hum.1994.5.9-1079
The paper
Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M.-T., Huang, W.-M., Johnson, D. E., Anderson, S. C., Wen, S. F., Bookstein, R., Shepard, H. M., & Gregory, R. J. (1994). Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer. Human Gene Therapy. https://doi.org/10.1089/hum.1994.5.9-1079

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.